# Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease

**Authors:** Halvard Bonig, Mareike Verbeek, Peter Herhaus, Krischan Braitsch, Gernot Beutel, Christoph Schmid, Nadine Müller, Gesine Bug, Michaela Döring, Arend von Stackelberg, Johanna Tischer, Francis Ayuk, Gerald Wulf, Udo Holtick, Lisa‑Marie Pfeffermann, Bernd Jahrsdörfer, Hubert Schrezenmeier, Selim Kuci, Zyrafete Kuci, Anke Zens, Michael Tribanek, Robert Zeiser, Sabine Huenecke, Peter Bader

PMC · DOI: 10.1186/s12967-024-05348-8 · Journal of Translational Medicine · 2024-06-13

## Full-text entities

- **Diseases:** graft-versus-host disease (MESH:D006086)
- **Chemicals:** ruxolitinib (MESH:C540383)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11170808/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC11170808/full.md

---
Source: https://tomesphere.com/paper/PMC11170808